Texas Capital Bancshares, Inc. Announces Date for Q3 2024 Operating Results DALLAS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the third quarter of 2024 before market on Thursday, October 17, 2024. Executive management will host a conference call and webcast to discuss third quarter 2024 operating results on Thursday, October 17, 2024, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number to ...
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development for the proposed treatment and long-term maintenance therapy of acromegaly. “This NDA submission brings us one step closer to our goal of delivering a new generation of therapy that can help people living...
Texas Capital Launches Government Money Market Exchange Traded Fund First-of-its-kind Money Market ETF to trade under the ticker MMKT DALLAS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bank Private Wealth Advisors, a subsidiary of Texas Capital Bank, and the Texas Capital Funds Trust today announced the launch of the Texas Capital Government Money Market ETF (NYSE: MMKT) (the “MMKT ETF” or “Fund”). This innovative and first-of-its-kind ETF will hold highly liquid, short-term U.S. government debt instruments and cash equivalents, providing an exchange-traded investment option for i...
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 120,200 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to t...
Texas Capital Bancshares, Inc. Shares Strategic Business Update Three years into its enterprise-wide transformation, firm reports significant progress towards financial and strategic targets DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc., the parent company of Texas Capital, led by President & CEO, Rob C. Holmes, today announced a series of actions that materially progresses the firm towards realization of the performance targets outlined in its strategic plan, communicated on . “Three years after announcing our strategic plan, we are pleased with the tre...
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September. Morgan Stanley 22nd Annual Global Healthcare Confer...
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the empl...
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent Cushing’s Syndrome Expected by End of 2024 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for en...
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced the launch of the healthcare provider (HCP) educational website and initiative, the purpose of which is to spotlight the significant challenges and burdens many people living with acromegaly experience when managing their disea...
Texas Capital Announces Private Credit Strategy Tim Laczkowski Appointed to Lead Texas Capital’s Inaugural Direct Lending Fund DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the launch of its Texas Capital Direct Lending (“TCDL”) platform. Focused on providing non-bank private capital to the middle market, TCDL will form an integral part of Texas Capital’s Corporate & Investment Bank and will enable Texas Capital clients and prospects to access a wider array of capital solutions. Texas Capital ...
Texas Capital Appoints Todd Jordan to Serve as Austin Market President and Leader of Austin Middle Market Banking DALLAS, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that Todd Jordan has joined Texas Capital as Austin Market President and leader of Austin Middle Market Banking. In his new role, Jordan is responsible for delivering best-in-class products and solutions with a strong focus on client service, driving Texas Capital’s strategy and instilling the firm’s culture across Central Texas. Jord...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.